A June 2 FDAnews.com article said, “The report found the overall likelihood of approval for all developmental candidates in Phase 1 trials to be 9.6 percent, with that number climbing to 11.9 percent if oncology candidates are excluded.”
A deeper dive into BIO’s “Clinical Development Success Rates 2006-2015” shows exactly 7,455 development programs across 1,103 companies were recorded and analyzed.
